Karyopharm Therapeutics Inc. (KPTI)

Market Cap	204.77M +404.3%
Revenue (ttm)	151.12M +6.3%
Net Income	-194.97M
EPS	-14.19
Shares Out	22.55M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	262,513
Open	9.04
Previous Close	9.07
Day's Range	8.85 - 9.23
52-Week Range	3.65 - 10.99
Beta	0.82
Analysts	Buy
Price Target	13.50 (+48.68%)
Earnings Date	May 14, 2026

About KPTI

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myelom...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 6, 2013
• Employees: 228
• Stock Exchange: NASDAQ
• Ticker Symbol: KPTI
• Website: https://www.karyopharm.com

Financial Performance

In 2025, Karyopharm Therapeutics's revenue was $146.07 million, an increase of 0.57% compared to the previous year's $145.24 million. Losses were -$196.04 million, 156.5% more than in 2024.

Analyst Summary

According to 7 analysts, the average rating for KPTI stock is "Buy." The 12-month stock price target is $13.5, which is an increase of 48.68% from the latest price.

Price Target

$13.5

(48.68% upside)

Analyst Consensus: Buy